Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Solventum Corporation reported mixed results for the quarter ended June 30, 2026. Total net sales were $2,209 million, up from $2,161 million a year earlier, with organic sales growth of 9.5% driven by MedSurg and Dental Solutions and aided by about $125 million of advanced customer orders ahead of a July 2026 ERP deployment, which is expected to pressure third-quarter sales.
Quarterly net income was $92 million and diluted earnings per share were $0.53, little changed from the prior year, while operating income declined to $181 million as higher selling, general and administrative costs offset margin gains from lower cost of product. Results included a $100 million pre-tax benefit from IEEPA tariff refunds recorded in cost of product and $204 million of legal charges, mainly related to product litigation, which increased accrued litigation costs to $235 million.
For the first six months of 2026, net sales were $4,216 million versus $4,231 million and net income fell to $105 million from $227 million, reflecting the absence of a prior-year tax benefit, restructuring and legal costs. Operating cash flow was $38 million, while the company repurchased $355 million of stock and ended June with $403 million in cash and $5,079 million of total debt. Management is executing its four-year “Transform for the Future” program, targeting about $500 million in annual cost savings for roughly $500 million in cumulative pretax costs, and has announced plans to pursue a separation of the Health Information Systems business.
Solventum Corporation reported second-quarter 2026 net sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. GAAP diluted EPS was $0.53, while adjusted diluted EPS was $2.55, a 50.9% increase, as adjusted operating margin expanded to 28.4% from 21.9%.
Operating cash flow reached $227 million and free cash flow was $144 million, helped by timing of tax payments and insurance proceeds. Year-to-date, GAAP net income was $105 million versus $227 million a year earlier, though adjusted diluted EPS rose to 4.02 from 3.03.
The company announced plans to separate its Health Information Systems segment to sharpen its MedTech focus and raised full-year 2026 guidance, now expecting organic sales growth of 2.5%–3.0%, adjusted EPS of $7.10–$7.20, and free cash flow of $200–$300 million.
Solventum Corporation announced its intention to pursue a separation of its Health Information Systems business as part of a broader portfolio optimization and three‑phase transformation strategy. The goal is to create a more focused MedTech company centered on MedSurg and Dental Solutions while positioning Health Information Systems for independent growth.
Health Information Systems is described as a leading healthcare software business generating $1.4 billion in net sales for the twelve months ended December 31, 2025. Its solutions are deployed in 30+ countries, used by more than 75% of U.S. hospitals, and process approximately 660 million clinical documents monthly. The business operates in a roughly $10 billion addressable market estimated to be growing 5–6% annually, with a differentiated offering in revenue cycle and performance management, clinician productivity, and AI‑driven autonomous coding.
Solventum is evaluating a range of separation alternatives, including forming an independent company, combining with a larger player, or other structures, with a targeted completion window of 12 to 18 months. The company notes there is no assurance a separation will occur and that any transaction would require Board and regulatory approvals. Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC are financial advisors, and Cleary Gottlieb Steen & Hamilton LLP is legal counsel.
Solventum Corporation appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. He will report to Chief Financial Officer Wayde McMillan, serve as the company’s Principal Accounting Officer for SEC reporting, and replace Mary Wilcox following her previously announced retirement.
Zieselman, age 50, joins from Surgery Partners, Inc., where he was Senior Vice President, Corporate Finance and Controller. His prior roles include senior finance leadership positions at Stryker Corporation, Covanta Holding Corporation, Cendant Corporation and Avaya Inc. He began his career at PricewaterhouseCoopers, is a licensed CPA, and graduated summa cum laude from Rider University.
His compensation includes an annual base salary aligned with role scope and experience, a target annual bonus of 50% of base salary, eligibility for an annual long-term incentive target award of $500,000, a cash sign-on bonus of $130,000, and an initial grant of $600,000 in restricted stock units vesting in three equal installments, plus participation in the Solventum Executive Severance Plan.
Solventum Corporation reports the resolution of a Delaware Court of Chancery class action that challenged certain advance notice and stockholder nomination provisions in its By-laws. The company had already amended the challenged By-law provisions on September 20, 2024.
Following the amendment, the plaintiff moved to dismiss the case as moot but sought attorneys’ fees and expenses. After arm’s-length negotiations, Solventum agreed to pay $120,000 to the plaintiff’s counsel in full satisfaction of all fee and expense claims related to the By-laws amendment. On June 2, 2026, the Court entered an order closing the case and directing that notice of the agreed fee payment be provided through this report, without reviewing or passing judgment on the amount or reasonableness of the fees.
Solventum Corporation has updated its executive severance arrangements. On May 21, 2026, the board’s Talent Committee approved a new Solventum Executive Severance Plan, effective June 1, 2026, replacing the prior plan adopted in April 2024.
The plan covers certain employees, including executive officers, if they are involuntarily terminated without misconduct or leave for good reason, subject to a release of claims. Eligible participants may receive cash severance based on continued base salary for roughly 9 to 24 months, continued incentive eligibility, a lump‑sum for medical and dental coverage, and specified equity award treatment.
For direct reports to the Chief Executive Officer, the plan generally provides 12 months of base salary plus prorated incentive compensation after an eligible termination, while current executives who previously qualified for 18 months of salary keep that level for two years. It also clarifies forfeiture and limited vesting rules for equity awards and preserves certain grandfathered rights under earlier grants.
Solventum Corporation reported the results of its annual shareholder meeting held on May 15, 2026. Shareholders elected four Class II directors—Carlos Albán, Susan D. DeVore, Shirley Edwards, and Dr. Bernard A. Harris Jr.—each receiving over 113 million votes in favor, with additional broker non-votes recorded.
Shareholders also approved, on an advisory basis, the compensation of Solventum’s named executive officers, with 105,240,522 votes for and 36,603,358 against. Finally, shareholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 156,439,674 votes for and minimal opposition.
ALBAN CARLOS reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carlos Alban received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents the right to receive 1 share of Solventum common stock upon settlement, so this award covers 3,300 underlying shares. The RSUs were granted at no cash cost and will fully vest on May 15, 2027, if he continues serving through that date. Following this grant, Alban holds 3,300 RSUs directly, reflecting a routine, compensation-related equity award rather than an open-market share purchase or sale.
COX CARRIE SMITH reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carrie Smith Cox received a grant of 4,848 Restricted Stock Units, each representing one share of common stock upon settlement. These RSUs were awarded at no cash cost and will fully vest on May 15, 2027, if her service continues through that date.
Solventum Corp director Susan D. DeVore received a grant of 3,300 Restricted Stock Units (RSUs) that convert into the same number of common shares upon settlement. The award was given at no cash cost to her and represents equity-based compensation rather than an open-market purchase.
The RSUs are scheduled to fully vest on May 15, 2027, provided she continues to serve through that date. Following this grant, her reported holdings in RSUs tied to common stock total 3,300 units, aligning her compensation more closely with future company performance.